Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study

Figure 1 Flow chart of the selection of the eligible study population in the final analysis. AGE: Advanced glycation end product; NAFLD: Non-alcoholic fatty liver disease.

Figure 2 Boxplot showing the distribution of advanced glycation end product values in serum in the group of participants with mild steatosis and the group of participants with moderate/severe pooled steatosis. Data are shown as median ± inter-quartile range. ^bP< 0.001. AGE: Advanced glycation end product; RFU: Relative fluorescent units.

Figure 3 Receiver operating characteristic curves and corresponding areas under the curve of models to predict non-alcoholic fatty liver disease-associated steatosis. ROC: Receiver operating characteristic; CI: Confidence interval.